News | June 02, 2026
Ebola vax on the anvil?
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
Based in the global marketing function, he will be responsible for strengthening the company's visibility among sponsors, partners and industry stakeholders worldwide
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
The collaboration introduces a flexible, end-to-end CDx framework designed to adapt to shifting regulatory environments
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
The approval is supported by results from the Phase 3 SWOG 1826 trial
While overall survival data remain immature, the results pointed to a favourable trend.
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
The technology enables clinicians to assess brain tissue and microvascular reperfusion directly in the angiography suite, potentially improving stroke treatment decisions and patient outcomes
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
